---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-026063"
form_type: "8-K"
ticker: "FULC"
cik: "0001680581"
company_name: "Fulcrum Therapeutics, Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:48:28.743965+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Fulcrum Therapeutics reports Q4 2024 net loss $16.6M; cash $241M, runway into at least 2027

## Summary
- Full-year 2024 net loss $9.7M vs $97.3M in 2023, driven by $80M Sanofi upfront payment.
- Cash and marketable securities $241.0M as of Dec 31, 2024, sufficient into at least 2027.
- Phase 1b PIONEER trial of pociredir in SCD: 10 patients enrolled in 12 mg cohort; data expected mid-2025.
- Plan to submit IND for Diamond-Blackfan anemia program in Q4 2025.
- Phase 3 REACH trial (losmapimod) data to be presented at MDA Conference on March 19, 2025.

## SEC filing metadata
- accession: 0000950170-25-026063
- form_type: 8-K
- ticker: FULC
- cik: 0001680581
- company_name: Fulcrum Therapeutics, Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1680581/000095017025026063/0000950170-25-026063-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1680581/000095017025026063/fulc-20250225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-026063
- JSON: https://secwatch.observer/filing/0000950170-25-026063.json
- Plain text: https://secwatch.observer/filing/0000950170-25-026063.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.